Project Grant R21EB040263
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the Department of Health and Human Services National Institutes of Health, awarded the University of Texas at Arlington $339,676 on August 18, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop light-responsive osmium compounds as metallo-reagents for biomedical imaging and photoactivation. The project develops osmium-based...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of Texas at Arlington $378,411 on April 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop super-resolution tomographic imaging technology for deep tissue visualization. The project aims to overcome diffraction limits inherent in existing super-resolution imaging modalities—including super-resolution fluorescence...
- The National Institute of Biomedical Imaging and Bioengineering awarded The University of Texas Southwestern Medical Center $138,813 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to support Dr. Mai Thuan Huynh's transition to independent investigator status in metabolism and molecular imaging research. The award funds design, synthesis, and validation of advanced carbon tracers to image...
- The National Institute of Biomedical Imaging and Bioengineering awarded the Trustees of Boston University $232,550 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a mid-infrared photothermal fiber probe for label-free imaging and biomolecular composition analysis in endoscopic applications. The project will develop a fiber-based probe that integrates mid-infrared photothermal imaging with...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of Texas at Dallas $486,805 on July 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop margination-mediated delivery and glutathione-triggered release mechanisms enabled by renal-clearable gold nanoparticles for fluorescence-guided surgery of brain metastases. The project addresses a clinical gap: current...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of Cincinnati Sponsored Research Services Division $398,400 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop chemically-modified aptamer electrochemical sensors for ultra-sensitive biomonitoring. The research advances continuous biochemical monitoring technology to detect biomarkers at picomolar-to-nanomolar...
- The National Science Foundation Division of Chemical, Bioengineering, Environmental, and Transport Systems awarded The University of Texas at San Antonio $153,759 on December 1, 2025, to develop multimodal amyloid probes for early detection of protein aggregates associated with Alzheimer's disease, Type II diabetes, and other amyloid diseases under the Engineering program (CFDA 47.041). The project will engineer a new class of AIE@βPS probes—aggregation-induced emission molecules conjugated with...
- The National Institute of General Medical Sciences, a component of the Department of Health and Human Services National Institutes of Health, awarded 37Degrees, Inc. $360,247 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859, assistance type: Project Grant). The award funds development of photoacoustic microscopy systems for non-destructive, three-dimensional imaging of live and incubated engineered tissue. The project addresses a critical gap in...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of California, Santa Barbara $582,137 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop electrochemical aptamer-based sensors for long-duration, real-time molecular measurements in living tissue. The research aims to extend the in vivo operational lifespan of electrochemical aptamer-based sensors beyond their...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded The University of Texas Southwestern Medical Center $449,900 on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop new methods for detecting protein phosphorylation in cells. The project will exploit a novel bacterial effector protein, Legionella pneumophila LnaB, which attaches adenosine monophosphate...
The National Institute of Biomedical Imaging and Bioengineering, a component of the Department of Health and Human Services National Institutes of Health, awarded $184,063 to the University of Texas at San Antonio on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award funds development of forced-dimerization activated photoacoustic aptamer switch sensors (FDA-PASS), optical probes designed to enable molecular imaging at centimeter depths in living tissue. Unlike conventional fluorescence-based probes limited to less than 1 millimeter imaging depth, FDA-PASS probes translate molecular recognition into measurable absorption spectral shifts detectable by photoacoustic imaging. In Aim 1, the recipient will design and construct FDA-PASS probes based on aptamer-cDNA hybrids modified with identical dyes (such as indocyanine green), with forced dimerization of the dye upon hybridization generating distinct absorption signatures upon target binding. A lactate-sensitive FDA-PASS probe will be developed and optimized for sensitivity, specificity, and reversibility across physiologic ranges as proof of concept. In Aim 2, the optimized probe will be validated in vivo by mapping lactate dynamics in a mouse model of triple-negative breast cancer, enabling the first noninvasive three-dimensional visualization of lactate heterogeneity in tumors. The award period runs from September 1, 2026, to August 31, 2028, with place of performance in San Antonio, Texas. This is a project grant, the assistance type for hypothesis-, design-, technology-, or device-driven research supporting discovery and applied research in biomedical imaging and bioengineering.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $184.1k | 8/25/26 |